SearcharxivSearch

arXiv subjects

Ali Kishk

Publications and source records attributed to Ali Kishk.

2 recordsLinked to original sources

Fact or Fake? Assessing the Role of Deepfake Detectors in Multimodal Misinformation Detection

In multimodal misinformation, deception usually arises not just from pixel-level manipulations in an image, but from the semantic and contextual claim jointly expressed by the image-text pair. Yet most deepfake detectors, engineered to detect pixel-level forgeries, do not account for claim-level meaning, despite their growing integration in automated fact-checking (AFC) pipelines. This raises a central scientific and practical question: Do pixel-level detectors contribute useful signal for verifying image-text claims, or do they instead introduce misleading authenticity priors that undermine evidence-based reasoning? We provide the first systematic analysis of deepfake detectors in the context of multimodal misinformation detection. Using two complementary benchmarks, MMFakeBench and DGM4, we evaluate: (1) state-of-the-art image-only deepfake detectors, (2) an evidence-driven fact-checking system that performs tool-guided retrieval via Monte Carlo Tree Search (MCTS) and engages in deliberative inference through Multi-Agent Debate (MAD), and (3) a hybrid fact-checking system that injects detector outputs as auxiliary evidence. Results across both benchmark datasets show that deepfake detectors offer limited standalone value, achieving F1 scores in the range of 0.26-0.53 on MMFakeBench and 0.33-0.49 on DGM4, and that incorporating their predictions into fact-checking pipelines consistently reduces performance by 0.04-0.08 F1 due to non-causal authenticity assumptions. In contrast, the evidence-centric fact-checking system achieves the highest performance, reaching F1 scores of approximately 0.81 on MMFakeBench and 0.55 on DGM4. Overall, our findings demonstrate that multimodal claim verification is driven primarily by semantic understanding and external evidence, and that pixel-level artifact signals do not reliably enhance reasoning over real-world image-text misinformation.

cs.CV

DCcov: Repositioning of Drugs and Drug Combinations for SARS-CoV-2 Infected Lung through Constraint-Based Modelling

The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no effective antiviral drug except treatments for symptomatic therapy. Flux balance analysis is an efficient method to analyze metabolic networks. It allows optimizing for a metabolic function and thus e.g., predicting the growth rate of a specific cell or the production rate of a metabolite of interest. Here flux balance analysis was applied on human lung cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to reposition metabolic drugs and drug combinations against the replication of the SARS-CoV-2 virus within the host tissue. Making use of expression data sets of infected lung tissue, genome-scale COVID-19-specific metabolic models were reconstructed. Then host-specific essential genes and gene-pairs were determined through in-silico knockouts that permit reducing the viral biomass production without affecting the host biomass. Key pathways that are associated with COVID-19 severity in lung tissue are related to oxidative stress, as well as ferroptosis, sphingolipid metabolism, cysteine metabolism, and fat digestion. By in-silico screening of FDA approved drugs on the putative disease-specific essential genes and gene-pairs, 45 drugs and 99 drug combinations were predicted as promising candidates for COVID-19 focused drug repositioning (https://github.com/sysbiolux/DCcov). Among the 45 drug candidates, six antiviral drugs were found and seven drugs that are being tested in clinical trials against COVID-19. Other drugs like gemcitabine, rosuvastatin and acetylcysteine, and drug combinations like azathioprine-pemetrexed might offer new chances for treating COVID-19.

q-bio.MN